About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive and R/R CLL After 3-Year FollowUp Yielded High Responsive Durable Rates
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Jennifer Woyach
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Jennifer Woyach
444 views
October 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Chronic Lymphocytic Leukemia
13:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Shifting Standard of Care for Frontline Therapy of CLL: Which Patien…
Feat.
N. Jain
11:37
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CLL State of the Art Update: Ibrutinib Prolongs PFS Compared to CIT,…
Feat.
J. Brown
15:20
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Discussion on the Next Generation Small Molecules in CLL: 2nd Genera…
Feat.
J. Woyach
05:46
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
62 y/o Male Diagnosed With CLL, Treated w/Mono Retuximab, Differenti…
Feat.
A. Ferrajoli
04:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
72 y/o Female w/Relapsed Rai Stage IV CLL Treated w/Ibrutinib and Ri…
Feat.
A. Ferrajoli
06:07
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
63 y/o Male w/Untreated CLL Rai I, Acute Hepatitis and Fever Work-Up…
Feat.
A. Ferrajoli
13:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CAR-T Cell Therapy in Chronic Lymphocytic Leukemia (CLL): Manageable…
Feat.
T. Siddiqi
16:05
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Reassessing Prognostic Markers (IGHV, TP53, CD49d, and B2M) in the E…
Feat.
A. Wiestner
06:23
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive an…
Feat.
J. Woyach
07:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CLL and Therapy Related Myeloid Neoplasia in Chemoimmunotherapy Era:…
Feat.
A. Lenartova
